©2024 Stanford Medicine
PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19)
Not Recruiting
Trial ID: NCT04347954
Purpose
The study aims to determine the safety and efficacy of povidone-iodine (PVP-I) containing
nasal sprays as compared to isotonic saline nasal sprays in COVID-19 positive patients. The
primary outcome measure is SARS-CoV-2 viral titers in the nasal cavity and nasopharynx. In
vitro studies have shown PVP-I to be highly virucidal against the viruses which cause SARS
and MERS. Additionally, clinical studies have shown PVP-I saline sprays to be well tolerated
in human subjects. PVP-I oral rinses and sprays have been trialed as methods to reduce the
incidence and symptoms of viruses which cause the "common cold."
Official Title
Effect of PVP-I Nasal Sprays vs Normal Saline Nasal Sprays on SARS-CoV-2 Nasopharyngeal Titers
Stanford Investigator(s)
Jayakar V. Nayak, MD, PhD
Associate Professor of Otolaryngology - Head & Neck Surgery (OHNS) and, by courtesy, of Neurosurgery
Eligibility
Inclusion Criteria:
- Diagnosis of COVID-19 by lab test within 5 days of study participation
Exclusion Criteria:
- Allergy to "iodine," shellfish, or food dye
- Receiving intranasal steroids
- Sinus surgery within 30 days of beginning the study
- Intubated at the time of enrollment
- Pregnancy
- Participation in other COVID-19 studies - to be determined on a case by case basis
Intervention(s):
drug: Povidone-Iodine 2%
drug: Povidone-Iodine 0.5%
drug: Isotonic saline 0.9%
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Peter H Hwang, MD
650-725-6500